The EU is asking Australia to extend drug company monopolies. This could mean Australians wait longer for access to cheaper, generic medicines.
It’s exciting to think we’re on the brink of a genomic revolution in health care. But just because new technology becomes available, it doesn’t mean it should automatically be publicly funded.
A Grattan Institute report released today, Cutting a better drug deal, calls for a major shake-up of pharmacies and pharmaceutical pricing.